This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Prognosis for CVS Is Premature

NEW YORK ( TheStreet) -- CVS (CVS) reported stellar earnings Tuesday, with a question as craggy as Maine's coast: Can they keep it up?

Granted, that's always the concern at hand when a company reports solid earnings, as CVS did with earnings up 18% and revenue up 16%, both exceeding expectations.

But there's a caveat here.

Arch rival Walgreen (WAG) got into a contract dispute with Express Scripts (ESRX), which spelled temporary opportunity for CVS. The qualifier "temporary" is important because Walgreen and Express Script settled their quarrel.

With the dispute put to bed, though, CVS says they will retain at least 50% of those customers formerly loyal to Walgreen. That seems a touch high, but what are their chances? What's their plan?

Forbes and other media outlets, unfortunately, don't ask. They merely take CVS' claims as an article of faith -- which isn't good. Forbes' headline for example, assumes an ongoing cookbook-style formula for success. Just add water to those Walgreen customers and mix: "CVS' Prescription For Success: Record Sales, New Customers From Express Scripts Spat."

Forbes eventually addresses the fact that the spat is settled, but dismisses outright the impact it might have on CVS. "That CVS expects to retain half of the customers should ease investors' worries about whether the boost would be short-lived," Forbes wrote.

If only life were that simple: A company says what it expects and that forever quells investor concerns.

Instead of referring to a CVS "prescription" in their headline, The Wall Street Journal mentions their "confidence," more subjective and possibly fleeting. The Journal then, rightly, talks about CVS's retention plan: a predictable grab bag of advertising and promotion that CVS's management trumpeted, before throwing down an appropriate line of caution: "The market isn't quite buying all that bullishness."

That's better. CVS did well. But they still have to prove that those customers won't return to Walgreen in droves.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

At the time of publication, Fuchs had no positions in any of the stocks mentioned in this column.

Marek Fuchs was a stockbroker for Shearson Lehman Brothers and a money manager before becoming a journalist who wrote The New York Times' "County Lines" column for six years. He also did back-up beat coverage of The New York Knicks for the paper's Sports section for two seasons and covered other professional and collegiate sports. He has contributed frequently to many of the Times' other sections, including National, Metro, Escapes, Style, Real Estate, Arts & Leisure, Travel, Money & Business, Circuits and the Op-Ed Page.

For his "Business Press Maven" column on how business and finance are covered by the media, Fuchs was named best business journalist critic in the nation by the Talking Biz website at The University of North Carolina School of Journalism and Mass Communication. Fuchs is a frequent speaker on the business media, in venues ranging from National Public Radio to the annual conference of the Society of American Business Editors and Writers.

Fuchs appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs